Essential thrombocythemia

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005, 352: 1779-1790. 10.1056/NEJMoa051113. Johansson P: Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006, 32: 171-173. 10.1055/s-2006-939430. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC: Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000, 65: 132-139. 10.1034/j.1600-0609.2000.90236.x. Griesshammer M, Heimpel H, Pearson T: Essential thrombocythemia and pregnancy. Leuk Lymphoma. 1996, 22 (Suppl 1): 57-63. Harrison C: Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol. 2005, 129: 293-306. 10.1111/j.1365-2141.2005.05400.x. Elliott MA, Tefferi A: Thrombocythaemia and pregnancy. Best Pract Res Clin Haematol. 2003, 16: 227-242. 10.1016/S1521-6926(03)00019-7. Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, Guilmin F, Kiladjian JJ, Plessier A, Denninger MH, Casadevall N, Valla D, Brière JB: Relevance of the criteria commonly used to diagnose myeloproliferative disorders in patients with splanchnic thrombosis. Br J Haematol. 2005, 129: 553-560. 10.1111/j.1365-2141.2005.05490.x. Michiels JJ, Berneman Z, Bockstaele DV, van der Planken M, De Raeve H, Schroyens W: Clinical and laboratory features, pathology of platelet-mediated thrombosis and bleeding complications and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost. 2006, 32: 174-207. 10.1055/s-2006-939431. Van Genderen PJJ, Budde U, Michiels JJ, van Strik R, van Vliet HHMD: The reduction of large von Willebrand factor multimères in plama in essential thrombocythemia is related to the platelet count. Br J Haematol. 1996, 93: 362-965. 10.1046/j.1365-2141.1996.d01-1729.x. Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ: Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemost. 1997, 23: 371-377. Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Briere J: Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. Leuk Lymphoma. 1996, 22 (Suppl 1): 149-160. Murphy S, Peterson P, Illand H, Lazlo J: Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997, 34: 29-39. Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G: Essential thrombocythaemia. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Edited by: Jaffe ES, Harris NL, Stein H, Vardiman JW. 2001, Lyon, IARC press, 39-41. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia Vera. Nature. 2005, 434: 1444-1148. 10.1038/nature03546. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005, 366: 122- Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cel. 2005, 7: 387-397. 10.1016/j.ccr.2005.03.023. Kaushansky K: On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood. 2005, 105: 4187-4190. 10.1182/blood-2005-03-1287. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP: JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood. 2005, 106: 3370-3373. 10.1182/blood-2005-05-1800. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP: Refractory anemia with ringed sideroblasts associted with marked thrombocytosis (RAR-T), another myeloproliferative condition characterised by JAK2 V617F mutation. Blood. 2006, 108: 2173-2181. 10.1182/blood-2006-02-005751. Thiele J, Kvasnicka HM: Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003, 82: 148-152. Georgii A, Buhr T, Buesche G, Kreft A, Choritz H: Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma. 1996, 22 (Suppl 1): 15-29. Thiele J, Kvasnika HM: Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. Semin Throm Hemost. 2006, 32: 219-230. 10.1055/s-2006-939433. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, Longo G, Bosi A, Vannucchi AM: Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005, 19: 1847-1849. 10.1038/sj.leu.2403902. El Kassar N, Hetet G, Briere J, Grandchamp B: Clonality analysis of haematopoiesis in essential thrombocythemia: advantages of studying T-lymphocytes and platelets. Blood. 1997, 89: 128-134. Harnsson CN, Gale RE, Machin SJ, Linch DC: A large proportion of patients with a diagnosis of essential thrombocythaemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 1999, 93: 417-424. Chiusolo P, La Barbera EO, Laurenti L, Piccirillo N, Sora F, Giordano G, Urbano R, Mazzucconi MG, De Stefano V, Leone G, Sica S: Clonal hematopoiesis and risk of thrombosis in young female patient with essential thrombocythemia. Exp Hematol. 2001, 29: 670-676. 10.1016/S0301-472X(01)00640-3. Shih LY, Lin TL, Lai CL, Dunn P, Wu JH, Wang PN, Kuo MC, Lee LC: Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood. 2002, 100: 1596-1601. 10.1182/blood-2002-01-0195. Kladjian JJ, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N, Conejero C, Briere J, Fenaux P, Chomienne C, Grandchamp B: Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia. 2006, 20: 1181-1183. 10.1038/sj.leu.2404214. Dobo I, Donnard M, Girodon F, Mossuz P, Boiret N, Boukhari R, Allegraud A, Bascans E, Campos L, Pineau D, Turlure P, Praloran V, Hermouet S: Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera. Hematol J. 2004, 5: 161-167. 10.1038/sj.thj.6200344. Li Y, El Kassar N, Gardin C, Briere J: Clonality assay and megacaryocyte culture technics in essential thrombocythemia. Leuk Lymphoma. 1996, 22 (Suppl 1): 31-40. Kralovics R, Buser SA, Teo S-S, Coers J, Tichelli A, Skoda R: Comparisonn of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood. 2003, 102: 1869-1871. 10.1182/blood-2003-03-0744. Klippel S, Pahl HL: Molecular markers for the diagnosis of philadelphia chromosome negative myeloproliferative disorders. Pathol Biol (Paris). 2004, 52: 267-274. Horikawa Y, Matsumura I, Hashimoto K, Shiraga M, Kosugi S, Tadokoro S, Kato T, Miyazaki H, Tomiyama Y, Kurata Y, Matsuzawa Y, Kanakura Y: Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood. 1997, 90: 4031-4038. Li J, Xia Y, Kuter DJ: The platelet megakaryocyte receptor number and function are markedly decreased in patients with essential thrombocythemia. Br J Haematol. 2000, 111: 943-963. 10.1046/j.1365-2141.2000.02430.x. Griesshammer M, Klippel S, Strunck E, Temerinac S, Mohr U, Heimpel H, Pahl HL: PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann Hematol. 2004, 83: 364-370. 10.1007/s00277-004-0864-9. Campbell PJ, Green AR: Management of polycythemia vera and essential thrombocythemia. Hematology Am Soc Hematol Educ Program. 2005, 201-208. Goerttler PS, Steimle C, Marz E, Johansson PL, Andreasson B, Griesshammer M, Gisslinger H, Heimpel H, Pahl HL: The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood. 2005, 106: 2862-2864. 10.1182/blood-2005-04-1515. Messinezy M, Westwood NB, El-Hemaidi I, Marsden JT, Sherwood RS, Pearson TC: Serum erythropoietin values in erythroses and in primary thrombocythaemia. Br J Haematol. 2002, 117: 47-53. 10.1046/j.1365-2141.2002.03386.x. Messinezy M, Westwood NB, Woodstock SP, Strong RM, Pearson TC: Low serum erythropoietine: a strong diagnostic criterion of primary polycythaemia even at normal haemoglobin levels. Clin Lab Haematol. 1995, 17: 217-220. Mossuz P, Groupe d'Etudes Multicentriques des Syndrome MyeloProliferatifs (GEMSMP): Influence of the assays of endogenous colony formation and serum erythropoietin on the diagnosis of polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006, 32: 246-250. 10.1055/s-2006-939435. Sacchi S, Vinci G, Gugliotta L, Rupoli S, Gargantini L, Martinelli V, Baravelli S, Lazzarino M, Finazzi G: Diagnosis of essential thrombocythemia at platelet counts between 400 and 600 × 10(9)/L. Haematologica. 2000, 85: 492-495. Kondo T, Okabe M, Sanada M, Kurosawa M, Suzuki S, Kobayashi M, Hosokawa M, Asaka M: Familial essential thrombocythemia associated with one-base deletion in the 5'-untranslated region of the thrombopoietin gene. Blood. 1998, 92: 1091-1096. Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C, Delhommeau F, Casadevall N, Vainchenker W, Thomas G, Najman A: Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006, 108: 346-352. 10.1182/blood-2005-12-4852. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House. Virginia. J Clin Oncol. 1999, 17: 3835-3849. Michiels JJ, Berneman Z, Schroyens W, Kutti J, Swolin B, Ridell B, Fernando P, Zanetto U: Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph negative essential thrombocythemia. Ann Hematol. 2004, 83: 504-512. 10.1007/s00277-004-0877-4. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y: Interpretation of measured red cell mass and plasma volume in the adults: expert panel on radionuclides of the International Council for Standardization in Haematology. Br J Haematol. 1995, 89: 748-756. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR, United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005, 366: 1945-1953. 10.1016/S0140-6736(05)67785-9. Thiele J, Kvasnika HM, Zankhovich R, Diehl V: Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica. 2000, 85: 1126-1134. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, Vanelli L, Arcaini L, Burcheri S, Malcovati L, Lazzarino M, Cazzola M: Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006, 107: 3676-3682. 10.1182/blood-2005-09-3826. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S: Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004, 89: 215-232. Harrison C: Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol. 2005, 130: 153-165. 10.1111/j.1365-2141.2005.05543.x. Michiels JJ: Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia. Clin Appl Throm Hemost. 1999, 5: 247-251. Elliott MA, Tefferi A: Thrombosis and haemorrhage in polycythemia vera and essential thrombocythaemia. Brh J Haematol. 2005, 128: 275-290. 10.1111/j.1365-2141.2004.05277.x. Schwarz J, Pytlik R, Doubek M, Brychtova Y, Dulicek P, Campr V, Kren L, Penka M: Analysis of risk factors: the rationale of guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia. Sem Throm Hemost. 2006, 32: 231-245. 10.1055/s-2006-939434. Schafer AI: Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006, 107: 4214-4222. 10.1182/blood-2005-08-3526. Landolfi R, Di Gennaro L, Novarese L, Patrono C: Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for futures studies. Semin Thromb Hemost. 2006, 32: 251-259. 10.1055/s-2006-939436. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators: Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004, 350: 114-124. 10.1056/NEJMoa035572. Low dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia. Br J Haematol. 1997, 97: 453-456. 10.1046/j.1365-2141.1997.362682.x. Randi ML, Rossi C, Fabris F, Menapace L, Girolami A: Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia. Clin Appl Thromb Hemost. 1999, 5: 131-135. Van Genderen PJJ, Mulder PGH, Weleboer M, Van de Moesdijk D, Michiels JJ: Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol. 1997, 97: 179-84. 10.1046/j.1365-2141.1997.d01-2127.x. Ruggeri M, Castaman G, Rodeghiero F: Is Ticlopidine a safe alternative to management of myeloproliferative disorders. Haematologica. 1993, 78: 18-21. Cortelazzo S, Finazzi G, Ruggeri M, Vestri 0, Galli M, Rodeghiero F, Barbui T: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N EngI J Med. 1995, 332: 1132-1136. 10.1056/NEJM199504273321704. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR, United Kingdom Medical Research Council Primary Thrombocythemia 1 Study: Hydroxyurea compared to Anagrelide in High-risk essential thrombocythemia. N Engl J Med. 2005, 353: 33-45. 10.1056/NEJMoa043800. Barosi G, Besses C, Birgegard G: A unified definition of clinical resistance/intolerance to Hydroxycarbamide in essential thrombocythemia: Results of a concensus process by an International Working Goup. Leukemia in press. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A, Anagrelide Study Group: Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res. 2005, 29: 481-491. 10.1016/j.leukres.2004.10.002. Petitt RM, Silverstein MN, Petrone ME: Anagrelide for control of thrombocythemia in polycythemia vera and other myeloproliferative disorders. Semin Hematol. 1997, 34: 51-54. Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A: Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica. 2003, 88: 1130-1138. Griesshammer M, Bergmann L, Hafner M, Heimpel H, Seifned E, Bangerter M, Hehlmann R, Lengfelder E: Treatment and clinical course of essential thrombocythaemia (ET): preliminary results of a prospective multicenter trial [abstract]. Blood. 1998, 92 (Suppl 1): 1750- Radin AI, Kim HT, Grant BW, Bennett JM, Kirkwood JM, Stewart JA, Hahn RG, Dutcher JP, Wiernik PH, Oken MM, Eastern Cooperative Oncology Group: Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003, 98: 100-109. 10.1002/cncr.11486. Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G, Nordic Study Group for Myeloproliferative Disorders: A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006, 106: 2397-2405. 10.1002/cncr.21900. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, Menot ML, Massonnet G, Dutel JL, Ghomari K, Rousselot P, Grange MJ, Chait Y, Vainchenker W, Parquet N, Abdelkader-Aljassem L, Bernard JF, Rain JD, Chevret S, Chomienne C, Fenaux P: High molecular response rate of polycythemia vera patients treated with pegylated interferon {alpha}-2a. Blood. 2006, 108: 2037-2040. 10.1182/blood-2006-03-009860. Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Brusamolino E, Passamonti F, Volpe G, Pistorio A, Giardini I, Rocca B, Caresana M, Lazzarino M, Bernasconi C: Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia. 2002, 16: 2078-2083. 10.1038/sj.leu.2402638. Passamonti F, Malabarba L, Orlandi E, Pascutto C, Brusamolino E, Astori C, Barate C, Canevari A, Corso A, Bernasconi P, Cazzola M, Lazzarino M: Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br J Haematol. 2002, 116: 855-861. 10.1046/j.0007-1048.2002.03367.x. Passamonti F, Rumi E, Malabarba L, Arcaini L, Orlandi E, Brusamolino E, Pascutto C, Cazzola M, Lazzarino M: Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Ann Hematol. 2004, 83: 495-497. 10.1007/s00277-004-0882-7. Najean Y, Rain JD: Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997, 90: 3370-3379. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M: Life expectancy and prognostic factors for survival in polycythemia vera and essential thrombocythemia. Am J Med. 2004, 117: 755-761. 10.1016/j.amjmed.2004.06.032. Ruggieri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T: No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998, 103: 772-777. 10.1046/j.1365-2141.1998.01021.x. Randi MI, Luzzatto G, Fabris F: Low-risk essential thrombocythemia in patients younger than 40. Br J Haematol. 1999, 104: 929-10.1046/j.1365-2141.1999.1331b.x. Pagliaro P, Arrigoni L, Muggiasca ML, Poggio M, Russo U, Rossi E: Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. Am J Hematol. 1996, 53: 6-10. 10.1002/(SICI)1096-8652(199609)53:1<6::AID-AJH2>3.0.CO;2-V. Martinelli P, Martinelli V, Agangi A, Maruotti GM, Paladini D, Ciancia R, Rotoli B: Interferon alfa treatment for pregnant women affected by essential thrombocythemia: case reports and a review. Am J Obstet Gynecol. 2004, 191: 2016-2020. 10.1016/j.ajog.2004.05.001. Rozman C, Giralt M, Feliu E: Life expectancy of patients with chronic myeloproliferative disorders. Cancer. 1991, 67: 2658-2663. 10.1002/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C. Bazzan M, Tamponi G, Schinco P, Vaccarino A, Foli C, Gallone G, Pileri A: Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol. 1999, 78: 539-543. 10.1007/s002770050555. Tefferi A, Fonseca R, Pereira DL, Hoagland HC: A long term retospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001, 76: 22-28. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990, 8: 556-562. Stark P, Regev A, Blickstein D, Lahav M, Shaklai M: Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol. 1997, 56: 168-172. 10.1002/(SICI)1096-8652(199711)56:3<168::AID-AJH6>3.0.CO;2-W. Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, Heis N, Castaman G, Missiaglia E, Lechner K, Rodeghiero F: Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol. 2002, 71: 1-6. 10.1002/ajh.10153. Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ: Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost. 2002, 87: 802-807. Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, Woessner S, Sans-Sabrafen J, Rozman C, Montserrat E: Major vascular complications in essential thrombocythemia: a study of predictive factors in a series of 148 patients. Leukemia. 1993, 13: 150-154. Januten R, Juvonen E, Ikkalla E, Oksanen K, Antilla P, Ruutu T: The predictive value of vascular risk factors and gender for the developpement of thrombotic complications in essential thrombocythemia. Ann Hematol. 2001, 80: 74-78. 10.1007/s002770000244. Watson KV, Key N: Vascular complications of essential thrombocythemia: a link to cardiovascular risk factors. Br J Haematol. 1993, 83: 198-203. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C: The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol. 2006, 132: 244-245. 10.1111/j.1365-2141.2005.05858.x. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, Gilliland DG, Tefferi A: JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005, 131: 208-213. 10.1111/j.1365-2141.2005.05764.x. Bellucci S, Michiels JJ: The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006, 32: 381-398. 10.1055/s-2006-942759. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Manarini S, Finazzi G, Cerletti C, Barbui T: Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000, 96: 4216-4226. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F: Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006, 91: 169-175. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Antilla P, Ruutu T: Development of erythrocytosis in the course of essential thrombocythemia. Ann Hematol. 1999, 78: 219-222. 10.1007/s002770050505. Le Bousse-Kerdiles MC, Martyre MC: Dual implication of fibrogenic cytokines in the pathogenesis offibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol. 1999, 78: 362-371. 10.1007/s002770050595. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E: Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002, 118: 786-790. 10.1046/j.1365-2141.2002.03688.x. Anderson PO, Ridell B, Wadenvik H, Kutti J: Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment. Ann Hematol. 2000, 79: 40-42. 10.1007/s002770050007. Shibata K, Shimamoto Y, Suga K, Sano M, Matsuzaki M: Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation – a brief review of recent literature. Acta Haematol. 1994, 91: 84-88. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, Bordessoule D, Bauters F, Fenaux P: Acute leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998, 91: 616-622. Spivak JL, Barosi G, Tognoni G, Barbui T, Finazzi G, Marchioli R, Marchetti M: Chronic myeloproliferative disorders. Hematology Am Soc Hematol Educ Program. 2003, 200-224. Randi ML, Fabris F, Girolami A: Second malignancies in patients with essential thrombocythemia. Br J Haematol. 2002, 116: 293-294. 10.1111/j.1365-2141.2002.3346_1.x. Finazzi G, Barbui T: Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann Hematol. 1999, 78: 389-392. 10.1007/s002770050536. Finazzi G, Ruggieri M, Rodeghiero F, Barbui T: Second malignancies in patients with essential thrombocythemia treated with busulfan and hydroxyurea: long term follow up of a randomised clinical trial. Br J Haematol. 2002, 116: 924-924. Nielsen I, Hasselbalch HC: Acute leukemia and myelodysplasia in patients with Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol. 2003, 74: 26-31. 10.1002/ajh.10375. Campbell JP, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, Erber WN, Kusec R, Larsen TS, Giraudier S, Le Bousse-Kerdiles MC, Griesshammer M, Reilly JT, Cheung BY, Harrison CN, Green AR: Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations and role in leukemic transformation. Blood. Cervantes F: Modern management of myelofibrosis. Br J Haematol. 2005, 128: 583-592. 10.1111/j.1365-2141.2004.05301.x.